Moderna names Stephen Kelsey president of oncology company
This article was originally published in Scrip
Executive Summary
Cambridge, Massachusetts-based Moderna Therapeutics has named Dr Stephen Kelsey president of its oncology drug development company Onkaido Therapeutics – effective 21 July 2014. Launched in January, Onkaido is Moderna's first venture company, focused exclusively on developing and commercializing mRNA-based oncology treatments. Dr Kelsey joins the company from Medivation where he was senior vice-president of new projects. For his new role at Onkaido, Dr Kelsey will be relocating to Cambridge from San Francisco.